Jens Hennecke Joins Delenex Therapeutics As Business and Corporate Development Advisor

Schlieren/Zurich, 12 November 2013. Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA®Bodies, today announced that it has engaged Jens Hennecke, PhD, as Business and Corporate Development Advisor.

Dr. Jens Hennecke (46) has a strong track record in business development, corporate development and licensing. He brings extensive experience in the negotiation and closing of corporate alliances. Prior to joining Delenex and building his own business development advisory franchise, he held the position of Senior Vice President Business Development at Micromet, Inc. where he played a key role in establishing partnerships with major pharma companies, as well as in Micromet’s acquisition by Amgen in 2012. Dr. Hennecke holds a B.Sc. in biology from the University of Göttingen, Germany, and a Ph.D. from the ETH Zurich, Switzerland.

Dr. Thomas Hecht, Executive Chairman of Delenex mentioned, “We are pleased and proud to have attracted Jens with his international experience and strong business development and licensing background. We are convinced that Jens will add to the success of Delenex and spearhead our business development activities to add new partnerships.”

“I am very much looking forward to working with Delenex,” said Dr. Jens Hennecke. “Delenex has a strong pipeline of PENTRA®Bodies and advanced clinical projects, including topical treatments of dermatologic diseases. This provides for significant partnering opportunities beyond Novartis’ exclusive use of the platform for ophthalmic diseases.”

About Delenex Therapeutics AG

Delenex is a privately-held biopharmaceutical company focused on the development of locally or topically applied antibody therapeutics. Thereby Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of patients. Delenex’ proprietary PENTRA® platform will deliver such novel, potent and safe antibody therapeutics that are well suited for local/topical application.

Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).

For further details, please contact:

Jakob Schlapbach, CFO

Delenex Therapeutics AG

Wagistrasse 27

CH-8952 Schlieren/Zurich

E-mail: jakob.schlapbach@delenex.com

Website: www.delenex.com

Help employers find you! Check out all the jobs and post your resume.